KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Current Leases (2019 - 2026)

Twist Bioscience has reported Current Leases over the past 8 years, most recently at $10.4 million for Q1 2026.

  • Quarterly Current Leases fell 31.38% to $10.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Mar 2026, down 31.38% year-over-year, with the annual reading at $13.8 million for FY2025, 6.64% down from the prior year.
  • Current Leases was $10.4 million for Q1 2026 at Twist Bioscience, down from $12.2 million in the prior quarter.
  • Over five years, Current Leases peaked at $15.5 million in Q2 2025 and troughed at $10.4 million in Q1 2026.
  • The 5-year median for Current Leases is $14.4 million (2022), against an average of $14.1 million.
  • Year-over-year, Current Leases skyrocketed 117.47% in 2022 and then crashed 31.38% in 2026.
  • A 5-year view of Current Leases shows it stood at $14.2 million in 2022, then grew by 4.08% to $14.8 million in 2023, then increased by 1.5% to $15.0 million in 2024, then fell by 18.55% to $12.2 million in 2025, then dropped by 14.7% to $10.4 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Current Leases are $10.4 million (Q1 2026), $12.2 million (Q4 2025), and $13.8 million (Q3 2025).